PL3045471T3 - Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację - Google Patents

Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Info

Publication number
PL3045471T3
PL3045471T3 PL16158141T PL16158141T PL3045471T3 PL 3045471 T3 PL3045471 T3 PL 3045471T3 PL 16158141 T PL16158141 T PL 16158141T PL 16158141 T PL16158141 T PL 16158141T PL 3045471 T3 PL3045471 T3 PL 3045471T3
Authority
PL
Poland
Prior art keywords
alpha
sialylation
recombinant fsh
fsh containing
containing alpha
Prior art date
Application number
PL16158141T
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3045471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL3045471T3 publication Critical patent/PL3045471T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL16158141T 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację PL3045471T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP16158141.8A EP3045471B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
PL3045471T3 true PL3045471T3 (pl) 2017-10-31

Family

ID=39717519

Family Applications (6)

Application Number Title Priority Date Filing Date
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16158141T PL3045471T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację

Country Status (29)

Country Link
US (6) US8951967B2 (pl)
EP (7) EP2722339A1 (pl)
JP (7) JP2011519359A (pl)
KR (5) KR101622944B1 (pl)
CN (3) CN105906702A (pl)
AR (1) AR071479A1 (pl)
AU (5) AU2009237479B2 (pl)
BR (1) BRPI0910461B8 (pl)
CA (1) CA2725257A1 (pl)
CY (1) CY1115413T1 (pl)
DK (6) DK3144318T3 (pl)
ES (5) ES2629392T3 (pl)
FI (4) FI3098234T3 (pl)
FR (3) FR17C1020I2 (pl)
HR (5) HRP20140535T1 (pl)
HU (9) HUE033830T2 (pl)
IL (2) IL208538A (pl)
LT (8) LT3045471T (pl)
MX (3) MX2010011343A (pl)
NO (4) NO2017025I1 (pl)
NZ (1) NZ588381A (pl)
PL (6) PL2268666T3 (pl)
PT (6) PT3144318T (pl)
RU (3) RU2537268C2 (pl)
SA (1) SA109300228B1 (pl)
SI (6) SI3098234T1 (pl)
TW (1) TWI488640B (pl)
WO (1) WO2009127826A1 (pl)
ZA (1) ZA201007373B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
CA2990311A1 (en) 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP4427806A3 (en) 2017-09-01 2024-10-09 Ferring B.V. Composition for controlled ovarian stimulation
RS66871B1 (sr) 2018-04-30 2025-06-30 Ferring Bv Kompozicija za kontrolisanu stimulaciju jajnika
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
CN118922201A (zh) 2022-04-01 2024-11-08 辉凌公司 治疗不育症的混合方案
JP2025516966A (ja) 2022-05-26 2025-05-30 フェリング ベスローテン フェンノートシャップ 男性の不妊症の治療のための組成物及び方法
US20250367262A1 (en) 2022-07-08 2025-12-04 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
WO2025017533A1 (en) 2023-07-20 2025-01-23 Ferring B.V. Extended release drug-loaded microparticles

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
DK1015622T3 (da) 1997-01-16 2004-08-02 Neose Technologies Inc Praktisk sialylering in vitro af rekombinante glycoproteiner
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
PT1176976E (pt) 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
EP2600809B1 (en) 2010-08-03 2015-02-25 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
EP3144318B1 (en) 2020-09-23
SI2268666T1 (sl) 2014-07-31
PT2808340T (pt) 2016-11-21
HUS2500029I1 (hu) 2025-07-28
ZA201007373B (en) 2011-06-29
LTPA2025505I1 (pl) 2025-02-10
JP2011519359A (ja) 2011-07-07
US20150065695A1 (en) 2015-03-05
DK2268666T3 (da) 2014-05-12
SI3144318T1 (sl) 2020-12-31
AU2009237479B2 (en) 2014-05-15
KR101622944B1 (ko) 2016-05-23
TWI488640B (zh) 2015-06-21
DK4015527T3 (da) 2025-04-14
PL3144318T3 (pl) 2021-02-08
ES2468318T3 (es) 2014-06-16
IL230571A (en) 2015-11-30
DK3144318T3 (da) 2020-12-07
PT3045471T (pt) 2017-06-14
NO2025032I1 (no) 2025-07-14
CN105906703A (zh) 2016-08-31
ES2989729T3 (es) 2024-11-27
RU2014141994A (ru) 2016-05-10
RU2010141908A (ru) 2012-05-27
SI2808340T1 (sl) 2016-12-30
KR20190092608A (ko) 2019-08-07
JP2017060476A (ja) 2017-03-30
FR25C1003I1 (fr) 2025-02-28
HUE030652T4 (en) 2017-09-28
RU2745557C3 (ru) 2021-12-10
HRP20250313T1 (hr) 2025-05-09
KR20160056960A (ko) 2016-05-20
US9546204B2 (en) 2017-01-17
MX348622B (es) 2017-06-22
AR071479A1 (es) 2010-06-23
CN105906702A (zh) 2016-08-31
AU2017204258B2 (en) 2017-08-17
US12516094B2 (en) 2026-01-06
NO2025006I1 (no) 2025-01-16
RU2537268C2 (ru) 2014-12-27
JP6486310B2 (ja) 2019-03-20
WO2009127826A1 (en) 2009-10-22
PT4015527T (pt) 2025-04-10
FR17C1020I1 (pl) 2020-04-10
HUE071059T2 (hu) 2025-07-28
EP4015527B1 (en) 2025-01-22
IL208538A (en) 2014-03-31
EP2808340A1 (en) 2014-12-03
AU2014203277B2 (en) 2017-04-06
EP2808340B1 (en) 2016-08-17
AU2017204259B2 (en) 2017-08-17
LTPA2025525I1 (pl) 2025-07-25
HRP20140535T1 (hr) 2014-07-18
CY1115413T1 (el) 2017-01-04
US20160347811A1 (en) 2016-12-01
US9771407B2 (en) 2017-09-26
RU2682270C2 (ru) 2019-03-18
US20210332099A1 (en) 2021-10-28
CN102066414A (zh) 2011-05-18
NO2017025I1 (no) 2017-06-06
EP4015527A1 (en) 2022-06-22
AU2017225020A1 (en) 2017-09-28
SI4015527T1 (sl) 2025-05-30
AU2017204259A1 (en) 2017-07-20
HUE068565T2 (hu) 2025-01-28
RU2745557C1 (ru) 2021-03-29
HRP20241187T1 (hr) 2024-12-06
EP2268666B1 (en) 2014-03-12
HRP20170958T1 (hr) 2017-09-22
EP3098234B1 (en) 2024-07-31
BRPI0910461B8 (pt) 2021-05-25
FI3098234T3 (fi) 2024-10-31
FIC20250025I1 (fi) 2025-07-11
KR20180095140A (ko) 2018-08-24
NO2017050I1 (no) 2017-09-28
PL3098234T3 (pl) 2025-01-07
JP2018021037A (ja) 2018-02-08
AU2009237479A1 (en) 2009-10-22
RU2014141994A3 (pl) 2018-05-28
AU2017225020B2 (en) 2019-11-14
JP7316905B2 (ja) 2023-07-28
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
LT4015527T (lt) 2025-04-10
ES3023526T3 (en) 2025-06-02
JP2020040956A (ja) 2020-03-19
JP2015120696A (ja) 2015-07-02
KR20170110741A (ko) 2017-10-11
HUS2500008I1 (hu) 2025-02-28
US20180079794A1 (en) 2018-03-22
PL2808340T3 (pl) 2017-02-28
LT3098234T (lt) 2024-09-10
SI3098234T1 (sl) 2024-10-30
PL2268666T3 (pl) 2014-08-29
US20240327487A1 (en) 2024-10-03
FI4015527T3 (fi) 2025-04-29
FR25C1025I1 (fr) 2025-09-19
PT2268666E (pt) 2014-06-25
JP2024038000A (ja) 2024-03-19
CA2725257A1 (en) 2009-10-22
EP3045471B1 (en) 2017-03-29
NZ588381A (en) 2012-05-25
EP3098234A1 (en) 2016-11-30
DK3098234T3 (da) 2024-10-21
DK3045471T3 (en) 2017-06-26
US10995128B2 (en) 2021-05-04
US20110105398A1 (en) 2011-05-05
TW200948378A (en) 2009-12-01
HK1146284A1 (en) 2011-05-20
LT2808340T (lt) 2016-11-10
AU2014203277C1 (en) 2017-07-27
HK1199039A1 (en) 2015-06-19
BRPI0910461A2 (pt) 2018-03-27
LTPA2017018I1 (lt) 2017-06-26
HUS1700025I1 (hu) 2017-06-28
BRPI0910461B1 (pt) 2021-02-23
EP3045471A1 (en) 2016-07-20
HUS1700036I1 (hu) 2017-10-30
AU2017204258A1 (en) 2017-07-20
AU2014203277A1 (en) 2014-07-24
KR102108377B1 (ko) 2020-05-08
HUE030652T2 (en) 2017-05-29
PT3098234T (pt) 2024-10-21
KR20110005863A (ko) 2011-01-19
FR17C1020I2 (fr) 2020-04-10
MX355457B (es) 2018-04-19
US8951967B2 (en) 2015-02-10
SI3045471T1 (sl) 2017-07-31
EP2268666A1 (en) 2011-01-05
ES2610277T3 (es) 2017-04-26
JP2022031652A (ja) 2022-02-22
HRP20161520T1 (hr) 2016-12-30
HUS1700024I1 (hu) 2017-06-28
LTPA2017029I1 (lt) 2017-10-10
EP3144318A1 (en) 2017-03-22
LT3045471T (lt) 2017-07-10
HUE033830T2 (en) 2018-01-29
IL208538A0 (en) 2010-12-30
DK2808340T3 (en) 2016-12-05
FIC20250003I1 (fi) 2025-01-15
JP6762916B2 (ja) 2020-09-30
US11952407B2 (en) 2024-04-09
PT3144318T (pt) 2020-11-04
BRPI0910461A8 (pt) 2018-10-16
SA109300228B1 (ar) 2014-04-08
EP2722339A1 (en) 2014-04-23
ES2629392T3 (es) 2017-08-09

Similar Documents

Publication Publication Date Title
HRP20170958T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6- sialilaciju
UY33125A (es) Diaza-espiro-[5,5]-undecanos
IL208873A0 (en) Novel n-(2-amino-phenyl)-acrylamides
FI20080124A0 (fi) Läheis-Josephson-ilmaisin
FI20085362A0 (fi) Kahmari
BRPI1014211A2 (pt) "composição."
HUE051918T2 (hu) Alfa 2,3- és alfa 2,6-szialilációt tartalmazó rekombináns FSH
CN300893078S (zh) 瓶子(1)
TH105749B (th) ไทรซับสทิทิวเทด 1,2,4 ไทรแอโซล
FI20080380A0 (fi) Liikeanalysaattori
FI8353U1 (fi) Liitoskappale
FI7964U1 (fi) Liitoskappale
GB0705503D0 (en) The buffer
CN301237260S (zh) 瓶贴(消毒液)